In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) reported that Couchman Jonathan has picked up 2,414,302 of common stock as of 2017-05-24.
The acquisition brings the aggregate amount owned by Couchman Jonathan to a total of 2,414,302 representing less than 5.5% stake in the company.
For those not familiar with the company, Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Macugen is used for the treatment of neovascular (wet) age-related macular degeneration. Sylatron is used for the treatment of melanoma. CIMZIA is used for the treatment of moderate to severe rheumatoid arthritis and Crohn’s disease. CIMZIA is a biologic medicine that counteracts tumor necrosis factor (or TNF), which promotes inflammation of the joints in rheumatoid arthritis.
A glance at Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN)’s key stats reveals a current market capitalization of 10.88 Million based on 44.21 Million shares outstanding and a price at last close of $0.246 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-11-28, Icahn picked up 694,023 at a purchase price of $0.41. This brings their total holding to 6,598,886 as of the date of the filing.
On the sell side, the most recent transaction saw Lebuhn unload 21,119 shares at a sale price of $1.69. This brings their total holding to 42,189.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.